

REMARKS

The status of the claims is as follows:

Original:	1-17
Currently amended:	18-20
Previously presented:	None
Canceled:	21-23
Withdrawn:	None

Claims 1-20 will be pending with entry of this amendment.

The specification has been amended to contain a reference to the prior-filed provisional application for which a benefit of priority is being claimed.

The specification has been amended on page 40 to replace the term "protease" with "integrase". This amendment corrects an obvious and inadvertent error, since the specification as a whole makes it clear that the claimed compounds are integrase inhibitors.

An Abstract of the Disclosure has been added. The Abstract provided here is identical to the Abstract included with the application as originally filed and is identical to the abstract appearing on the cover sheet of the corresponding published PCT application.

Claims 18-20 have been amended to remove a multiple dependency, and claims 21-23 have been canceled.

No new matter has been added by the amendments to the specification, abstract, and claims. Entry of this amendment prior to examination is requested.

Respectfully submitted,

By: Kenneth R. Walton
Kenneth R. Walton, Reg. No. 32,951
Attorney for Applicants
MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel.: (732) 594-3462

Date: July 2, 2004